Amphotericin B colloidal dispersion: An improved antifungal therapy

Advanced Drug Delivery Reviews

Volumn 47, Issue 2-3, 2001, Pages 149-163

  Guo, Luke S S ^a  

^a ALZA CORPORATION   (United States)

Author keywords

Clinical safety and efficacy of ABCD; Lipid complex of amphotericin B; Pharmacokinetics of ABCD; Sodium cholesteryl sulfate; Sodium deoxycholate; Structure of ABCD

Indexed keywords

BLOOD; COLLOIDS; FUNGUS RESISTANCE; TOXICITY;

HEPATIC TOXICITY;

DRUG THERAPY;

AMPHOTECH; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX;

ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; FEBRILE NEUTROPENIA; GEL PERMEATION CHROMATOGRAPHY; GRAFT INFECTION; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; MEAN RESIDENCE TIME; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0035946611     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(01)00104-1     Document Type: Article

References (45)

1. Antifungal agents useful in therapy of systemic fungal infections
2. Treatment of systemic fungal infection: Recent progress and current problems
3. On the anatomy of AMB-cholesterol pores in lipid bilayer membranes
4. Equilibrium binding of amphotericin B and its methyl ester and borate complex to sterols
5. AMB-induced oxidative damage and killing of Candida albicans
6. Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effects of AMB
7. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes
8. Treatment of murine cryptococcosis with liposome-associated amphotericin B
9. Amphotericin B in liposomes: A novel therapy for histoplasmosis
10. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: A preliminary study
11. Treatment of hepatosplenic candidiasis with liposomal amphotericin B
12. Treatment of systemic fungal infections with liposomal amphotericin B
13. Mechanism of the selective toxicity f amphotericin B incorporated into liposomes
14. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B
15. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes
16. Novel antifungal drug delivery: Stable amphotericin B-cholesteryl sulfate discs
17. Cholesterol sulfate in rat tissues: Tissue distribution, developmental change and brain subcellular localization
18. Solubility and stability of amphotericin B in human serum
19. Interaction of plasma proteins and lipoproteins with amphotericin B
20. Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits
21. The lytic effect of polyene antifungal antibiotics on mammalian erythrocytes
22. Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion
23. Complexes of Amphotericin B and cholesteryl sulfate
24. Amphotericin B colloidal dispersion: Pre-clinical review
25. Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidiomycosis
26. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for the treatment of disseminated murine crytococcosis
27. Dose dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis
28. Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis
29. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats
30. Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats
31. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs
32. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to health volunteers
33. Safety of amphotericin B colloidal dispersion
34. Safety and efficacy of amphotericin B colloidal dispersion
35. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infection after bone marrow transplant
36. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients
37. Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients
38. Clinical efficacy of amphotericin B colloidal dispersion against infectious caused by Candida spp
39. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis
40. Treatment of invasive fungal infections in renal impaired patients with amphotericin B colloidal dispersion
41. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia
42. Rhinocerebral mucormycosis treated with amphotericin B colloidal dispersion in three patients
43. Successful treatment of cryptococcal meningitis with amphotericin B colloidal dispersion: Report of four cases
44. Successful treatment of zygomycosis of the paranasal sinuses with surgical debridement and amphotericin B colloidal dispersion
45. Failure of amphotericin B colloidal dispersion in the treatment of paracoccidioidomycosis